EyePoint Pharmaceuticals Announces Board Changes and New Appointments
Company Announcements

EyePoint Pharmaceuticals Announces Board Changes and New Appointments

EyePoint Pharmaceuticals (EYPT) just unveiled an update.

EyePoint Pharmaceuticals, Inc. underwent a board reshuffling as Dr. David R. Guyer and Dr. Anthony P. Adamis resigned to take up full-time positions at Merck & Co., with no disagreements with the company. Their departure led to a reduction in board size and the appointment of Fred Hassan, who will also join the Governance and Nominating Committee. Alongside this, new appointments were made to the Compensation and Science Committees. Hassan’s director compensation aligns with the company’s policy, including an option to acquire 60,000 shares of common stock. The company issued a press release regarding these changes on September 4, 2024.

See more data about EYPT stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyEyePoint price target lowered to $22 from $30 at H.C. Wainwright
TheFlyEyePoint price target lowered to $33 from $38 at Baird
TipRanks Auto-Generated NewsdeskEyePoint Pharmaceuticals Advances in Retinal Therapeutics
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App